Lumicell has announced the launch of LumiSystem for real-time cancer detection, making it commercially available in the US.

The system combines the FDA-approved Lumisight optical imaging agent and Lumicell direct visualisation system (DVS), enabling surgeons to visualise and remove cancerous tissue in real time during breast-conserving surgeries.

It claims to offer immediate feedback, potentially reducing the need for additional surgical procedures. The system’s real-time capabilities aim to achieve more complete tumour resection and improve patient outcomes.

In the INSITE pivotal trial, the LumiSystem demonstrated an 84% diagnostic accuracy and ‘improved’ surgical results for 10% of subjects by detecting cancerous tissue that was previously undetected by surgeons and pathologists.

This advancement offers a more comprehensive solution for breast-conserving surgery.

The primary objective of lumpectomy surgery is to excise the tumour and a margin of healthy tissue to ensure ‘negative margins’.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Enter your work email
First Name
Last Name
Company Name
Job title *
Phone number *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, existing surgical tools do not directly assess residual cancer within the surgical cavity, leading to limitations in pathology margin assessment and potential false readings.

These limitations often result in a 19% chance of residual cancer in cases deemed to have negative margins, the company noted.

Consequently, up to 36% of lumpectomy subjects may require a second surgery to remove missed cancerous tissue. The LumiSystem aims to significantly reduce these instances.

Lumicell CEO Howard Hechler said: “With LumiSystem’s commercial launch, we empower surgeons with a groundbreaking tool that detects cancer where and when it matters most, inside the breast cavity and in real-time.

“This launch reflects Lumicell’s unwavering commitment to enhancing surgical outcomes for patients.”

Lumicell specialises in developing fluorescence-guided imaging solutions to identify cancerous tissue during surgery.